J
Jedd D. Wolchok
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 795
Citations - 154490
Jedd D. Wolchok is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Ipilimumab & Immune system. The author has an hindex of 140, co-authored 713 publications receiving 123336 citations. Previous affiliations of Jedd D. Wolchok include Ludwig Institute for Cancer Research & University of York.
Papers
More filters
Journal ArticleDOI
Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.
Paul B. Chapman,Mark Klang,Michael A. Postow,Alexander N. Shoushtari,Ryan J. Sullivan,Jedd D. Wolchok,Phillip Wong,Margaret K. Callahan,Jonathan H. Zippin +8 more
TL;DR: A phase I trial combining phenformin (phen) and dabrafenib/trametinib (dab/Tram) was conducted in patients with metastatic BRAF V600-mutated melanoma (mel) cell lines as mentioned in this paper .
Journal ArticleDOI
Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.
F. Stephen Hodi,Vanna Chiarion-Sileni,Rene Gonzalez,Jean-Jacques Grob,Piotr Rutkowski,Christopher D. Lao,C. Lance Cowey,Dirk Schadendorf,John Wagstaff,Reinhard Dummer,Paola Queirolo,Michael Smylie,Mark S. Butler,Andrew G. Hill,Ivan Marquez-Rodas,Corey Ritchings,Leon A. Sakkal,Peter Feng Wang,Jedd D. Wolchok,James Larkin +19 more
TL;DR: In this article , NIVO + IPI has demonstrated durable clinical benefit at 7.5 y in pts with advanced melanoma in the phase 3 CheckMate 067 study, suggesting that being alive and progression-free for ≥ 3 y (PFS ≥ 3y) may be a good surrogate for longterm clinical benefit.
Journal ArticleDOI
Abstract 6150: Potential role of CD47 in T cell exhaustion program
Chien-Huan Weng,Fadi Samaan,Sadna Budhu,Levi Mangarin,Sebastien Monette,Cailian Liu,Stephane Pourpe,Linda Hamadene,Hong Zhong,Xia Yang,David F Schroder,Roberta Zappasodi,Pamela M. Holland,Jedd D. Wolchok,Taha Merghoub +14 more
TL;DR: It is confirmed that thrombospondin-1 (TSP-1), as an extracellular matrix protein and a ligand of CD47, contributes to driving the differentiation of CD8 T cells toward exhaustion, and shows that CD47 functions as a negative regulator for T cell proliferation and function during T cell priming.
Posted ContentDOI
Data from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
TL;DR: Eganelisib (IPI-549) is a first-in-class, orally administered, highly selective PI3Kγ inhibitor with antitumor activity alone and in combination with programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitors in preclinical studies as mentioned in this paper .
Journal ArticleDOI
549 Characterizing double positive T cells in the tumor microenvironment: a tale of promiscuous cell fates
Sara Schad,Andrew Chow,Heng Pan,Levi Mangarin,Roberta Zappasodi,Mathieu Gigoux,David Redmond,Daniel Hirschhorn-Cymerman,Sadna Budhu,Hong Zhong,Xia Yang,Olivier Elemento,Jedd D. Wolchok,Taha Merghoub +13 more
TL;DR: The re-expression of the opposite co-receptor following adoptive T cell transfer in B16 melanoma tumor bearing mice is demonstrated and highlighted the capability of single positive T cells to differentiate in response to antigen and local stimuli into novel T cell subsets with polyfunctional characteristics.